# US 6,159,478 A · Recombinant canine herpesviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,159,478 A
- Document ID: US6159478A
- Status: Granted
- Kind: A
- Application number: 09/092,409
- Filed: 1998-01-29
- Granted: 2000-12-12
- Earliest claimed: 1996-02-15
- Assignees: Heska Corporation
- Inventors: Elizabeth J. Haanes; Rexann S. Frank
- Web page: https://patentgrep.com/patent/US6159478A

## CPC

- C12N 15/86: Viral vectors
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/1211: {Thymidine kinase (2.7.1.21)}
- C12N 2710/16721: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16722: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16743: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention includes novel recombinant canine herpes virus (CHV) and novel recombinant CHV genomes, and particularly to those CHV and CHV genomes that contain heterologous nucleic acid molecules. The present invention also relates to the use of such genomes and viruses in a variety of applications, including as therapeutic compositions to protect animals from disease. The present invention also relates to novel isolated CHV nucleic acid molecules, to CHV proteins encoded by such nucleic acid molecules, and to antibodies raised against such CHV proteins as well as to the use of such CHV nucleic acid molecules, proteins and antibodies as therapeutic compositions to protect an animal from CHV. The present invention also includes constructs comprising CHV nucleic acid molecules that include heterologous nucleic acid molecules, to recombinant vectors including such constructs, and to the use of such constructs and vectors in the production of recombinant CHV and recombinant CHV genomes.

## Claims

### Claim 1

An isolated canine herpes vinis (CHV) CdUTPase protein encoded by a CHV nucleic acid molecule that hybridizes under stringent hybridization conditions with the CdUTPase gene.

### Claim 2 (depends on 1)

The CHV protein of claim 1, wherein said CHV protein is selected from the group consisting of: a CHV protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:16 and SEQ ID NO:80; and a CHV protein encoded by an allelic variant of a CHV nucleic acid molecule encoding a CHV protein comprising any of said amino acid sequences.

### Claim 3 (depends on 1)

A therapeutic composition comprising a CHV protein as set forth in claim 1.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant, a carrier, and a mixture thereof.

### Claim 5 (depends on 3)

A method to protect an animal from CHV comprising administering to said animal a therapeutic composition as set forth in claim 3.

### Claim 6 (depends on 5)

The method of claim 5, wherein said animal is a canid.

### Claim 7 (depends on 5)

The composition of claim 5, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant, a carrier, and a mixture thereof.

### Claim 8 (depends on 1)

The isolated CHV protein of claim 1, wherein said CdUTPase gene comprises nCdUTP.sub.459.

### Claim 9 (depends on 1)

The isolated CHV protein of claim 1, wherein said CdUTPase gene comprises nCdUTP.sub.918.

### Claim 10 (depends on 1)

The isolated CHV protein of claim 1, wherein said CHV nucleic acid molecule consists of a nucleic acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:77 and SEQ ID NO:79.

### Claim 11 (depends on 1)

The isolated CHV protein of claim 1, wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with a nucleic acid molecule selected from the group consisting of nCdUTP/CUL51.sub.743, nCUL.sub.1823 and nCdUT.sub.918.

### Claim 12 (depends on 1)

The isolated CHV protein of claim 1, wherein said CHV nucleic acid molecule comprises a CHV nucleic acid molecule selected from the group consisting of nCHin.sub.3000, nCHin.sub.1900, nCdUTP/CUL51.sub.743, nCdUTP.sub.459, nCUL.sub.1823, nCdUTP.sub.918, nCdUTP.sub.858, nCdUTP.sub.3200, and allelic variants of said CHV nucleic acid molecules.

### Claim 13 (depends on 1)

The isolated CHV protein of claim 1, wherein said CHV nucleic acid molecule is selected from the group consisting of: a CHV nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:77 and SEQ ID NO:79; and a nucleic acid molecule comprising an allelic variant of any of said CHV nucleic acid molecules.